Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Operating Expenses history runs 10 years deep, the most recent figure standing at $151.1 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 35.2% year-over-year to $151.1 million; the TTM figure through Mar 2026 stood at $563.8 million (up 49.36% YoY), while the FY2025 annual figure was $524.5 million, up 54.3% from the prior year.
• Operating Expenses for Q1 2026 stood at $151.1 million, up from $139.8 million in the prior quarter.
• The five-year high for Operating Expenses was $151.1 million in Q1 2026, with the low at $37.0 million in Q1 2022.
• The 5-year median for Operating Expenses is $74.2 million (2024), against an average of $83.2 million.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses jumped 66.68% in 2022, then grew 24.14% in 2023.
• Crinetics Pharmaceuticals' Operating Expenses stood at $48.3 million in 2022, then climbed by 29.82% to $62.7 million in 2023, then jumped by 51.21% to $94.7 million in 2024, then surged by 47.58% to $139.8 million in 2025, then rose by 8.07% to $151.1 million in 2026.
• Business Quant data shows CRNX's Operating Expenses at $151.1 million in Q1 2026, $139.8 million in Q4 2025, and $142.7 million in Q3 2025.